| Intercell AG Patent applications |
| Patent application number | Title | Published |
|---|
| 20120082674 | ENTEROCOCCUS ANTIGENS - The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from | 04-05-2012 |
| 20120045457 | NONTYPABLE HAEMOPHILUS INFLUENZAE ANTIGENS - The present invention relates to isolated nucleic acid molecules which encode an antigen from a nontypable | 02-23-2012 |
| 20110300169 | PHARMACEUTICAL COMPOSITION COMPRISING AN ANTIGEN - The invention relates to immunogenic compositions. In certain embodiments, the invention provides pharmaceutical compositions comprising an antigen, an immunostimulating substance selected form neuroactive compounds, hormones, compounds having a growth hormone activity, and mixtures thereof, and a polycationic polymer. | 12-08-2011 |
| 20110287013 | NUCLEIC ACIDS CODING FOR ADHESION FACTOR OF GROUP B STREPTOCOCCUS, ADHESION FACTORS OF GROUP B STREPTOCOCCUS AND FURTHER USES THEREOF - The present invention is related to nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and uses thereof. More particularly, the present invention is related to a polypeptide being such adhesion factors and comprising an amino acid sequence, whereby the amino acid sequence is selected from the group comprising SEQ ID NO 11 to SEQ ID NO 20, and the use of such polypeptide for the manufacture of a vaccine. | 11-24-2011 |
| 20110268740 | FULLY HUMAN INFLUENZA M2 SPECIFIC ANTIBODIES - The present invention relates to human antibodies, preferably to fully human antibodies, which are specifically binding to influenza M2e antigen. The invention further relates to individual light- and/or heavy chains of such antibodies, to nucleic acids encoding said antibodies or their light- and/or heavy chain, and to expression vectors for the expression of said anti-bodies. Furthermore, the invention relates to the use of said antibodies in the treatment and/or prevention of influenza A virus infection, preferably in humans. | 11-03-2011 |
| 20110243978 | ENTEROCOCCUS ANTIGENS - The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from | 10-06-2011 |
| 20110236414 | Bacterial Polysaccharide-Polypeptide Conjugate Compositions - The present invention relates to improved bacterial polysaccharide-polypeptide conjugate compositions, pharmaceutical compositions comprising such bacterial polysaccharide-polypeptide conjugate compositions, and the use of such compositions. Furthermore, the invention relates to the use of a combination of a peptide of the formula R | 09-29-2011 |
| 20110236410 | KLEBSIELLA ANTIGENS - The present invention relates to isolated nucleic acid molecules which encode an antigen, a vector which comprises such nucleic acid molecule, and a host cell comprising such vector. Furthermore, the invention provides antigens from a | 09-29-2011 |
| 20110091494 | PEPTIDES PROTECTIVE AGAINST S. PNEUMONIAE AND COMPOSITIONS, METHODS AND USES RELATING THERETO - The present invention relates to a protective peptide of | 04-21-2011 |
| 20100323003 | Flaviviridae Mutants Comprising a Deletion in the Capsid Protein for Use as Vaccines - The present invention relates to a mutant virus of the family flaviviridae, comprising a deletion in the capsid protein of at least 20 successive amino acids, without any further deletion, substitution or insertion mutation except of the amino acids next to the deletion, which may be substituted. | 12-23-2010 |
| 20100260790 | S. Pneumoniae Antigens - The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from | 10-14-2010 |
| 20100255034 | Streptococcus Pyogenes Antigens - The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from | 10-07-2010 |
| 20100203075 | CHLAMYDIA ANTIGENS - The present invention relates to isolated nucleic acid molecules which encode an antigen from a | 08-12-2010 |
| 20100166732 | SMALL STREPTOCOCCUS PYOGENES ANTIGENS AND THEIR USE - The present invention relates to a peptide consisting of one antigen of | 07-01-2010 |
| 20100136039 | BORRELIA ANTIGENS - The present invention relates to isolated nucleic acid molecules which encode a protein, isolated nucleic acid molecules which encode a hyperimmune serum reactive antigen, a vector which comprises such nucleic acid molecule, a host cell comprising such vector, a hyperimmune reactive antigen from | 06-03-2010 |
| 20100129388 | PROTECTIVE PROTEINS OF S. AGALACTIAE, COMBINATIONS THEREOF AND METHODS OF USING THE SAME - The invention relates to a composition comprising at least two protective proteins against | 05-27-2010 |
| 20100113340 | NUCLEIC ACIDS CODING FOR ADHESION FACTOR OF GROUP B STREPTOCOCCUS, ADHESION FACTORS OF GROUP B STREPTOCOCCUS AND FURTHER USES THEREOF - The present invention is related to nucleic acids coding for adhesion factors of group B | 05-06-2010 |
| 20100047263 | PEPTIDES PROTECTIVE AGAINST S. PNEUMONIAE AND COMPOSITIONS, METHODS AND USES RELATING THERETO - The present invention relates to a protective peptide or a functionally active variant of the protective peptide; a composition comprising at least two proteins selected from the group consisting of i) a first type of protective peptide or functionally active variant thereof, ii) a second type of protective peptide or functionally active variant thereof and iii) a supportive peptide or a functionally active variant thereof; one or more nucleic acid(s) encoding the protective peptide or functionally active variant thereof or the at least two proteins comprised in the composition; a pharmaceutical composition comprising the protective peptide or functionally active variant thereof, the composition, or the nucleic acid(s); a method of producing an antibody using the protective peptide or functionally active variant thereof or the composition; the use of the protective peptide or functionally active variant thereof and/or the composition and/or the nucleic acid(s) for the manufacture of a medicament for the immunization or treatment of a subject; a method of diagnosing a | 02-25-2010 |
| 20090186047 | HCV Vaccinations - The invention relates to a method for preventing or treating Hepatitis C Virus (HCVi) infections, wherein a HCV vaccine comprising an effective amount of at least one HCV T-cell antigen and a polycationic compound comprising peptide bonds is administered to a human individual bi-weekly at least 3 times. | 07-23-2009 |
| 20090060875 | HCV Vaccines for Chronic HCV Patients - The invention discloses the use of polycationic compounds for the preparation and manufacturing of medicaments, pharmaceutical compositions, especially vaccines for the treatment of patients with HCV chronic infections. | 03-05-2009 |
